Table 2 Correlations (r) between biomarker values at baseline for all patients and at week 24 for patients in the infliximab and placebo groups separately
Week 24: infliximab
Week 24: placebo
  • BAP, bone alkaline phosphatase; CTX, C-terminal cross-linking telopeptide of type I collagen; IL-6, interleukin-6; TGF-β, transforming growth factor β; VEGF, vascular endothelial growth factor.

  • *p<0.05; **p<0.005; ***p<0.0001; ****p = 0.0513.